Bayer Ends COVID-19 Vaccine Manufacturing Pact with CureVac

Bayer has dissolved its COVID-19 vaccine manufacturing deal with fellow German drugmaker CureVac, which announced last week that it was halting development of its messenger RNA-based COVID-19 vaccine, CVnCoV.

The manufacturing deal, which the companies announced in January, would have seen Bayer manufacture 160 million doses of CVnCoV in 2022 at its plant in Wuppertal, Germany.

Also last week, CureVac disclosed that its advance supply deal for CVnCoV with the European Commission will be terminated.

CureVac said it is shifting its focus to develop a second-generation shot with GlaxoSmithKline.